These findings are in agreement with recent studies that indicate a role for calreticulin in conferring a pro-invasive and metastatic phenotype in a range of cancers, including breast adenocarcinoma [24, 29], gastric cancer [19], and esophageal squamous cell carcinoma [18]. Here, CALR is linked to breast adenocarcinoma.